To help evaluate the benefits, risks, and regulatory considerations for robotic medical devices with autonomous or remote teleoperation capabilities, the US Food and Drug Administration (FDA) has issued and is inviting public input on a discussion paper.
According to the FDA, while rapid advances in AI, machine learning, and connectivity